Tenpoint Therapeutics has secured a total of $235 million through a combination of Series B equity financing and a non-dilutive credit facility, strengthening its balance sheet ahead of the commercial launch of YUVEZZI™, its newly approved presbyopia treatment.
The financing includes $85 million raised through a Series B preferred stock round led by Janus Henderson, EQT Nexus, Hillhouse and the British Business Bank. Existing investors, including EQT Life Sciences, Sofinnova Partners, F-Prime, Eight Roads, Qiming Venture Partners USA, AdBio and Wille, also participated. In parallel, the company entered into a $150 million senior secured term loan facility with Hercules Capital.
The funding milestone coincides with the US Food and Drug Administration’s approval of YUVEZZI™, making it the first and only dual-agent, once-daily eye drop approved for the treatment of presbyopia. The product combines carbachol and brimonidine tartrate and is designed to improve near vision while maintaining a favourable safety and tolerability profile.
Tenpoint Therapeutics plans to initiate the commercial launch of YUVEZZI in early Q2 2026, targeting a large and underserved patient population. Presbyopia affects an estimated 128 million people in the United States and nearly 2 billion individuals globally, representing one of the largest unmet needs in ophthalmology.
Headquartered across London and Seattle, Tenpoint operates as a global commercial-stage biotechnology company focused on therapies that rejuvenate vision in the aging eye. The company’s leadership team brings deep ophthalmology expertise, positioning it to execute a full-scale launch and drive adoption across eye care providers.
With regulatory approval secured and financing in place, Tenpoint Therapeutics is advancing its transition into a commercial-stage company, aiming to establish YUVEZZI as a differentiated treatment option in the growing presbyopia market.
